US Patent

US9902714 — Quinoxaline derivatives useful as FGFR kinase modulators

Formulation · Assigned to Astex Therapeutics Ltd · Expires 2035-03-26 · 9y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects new quinoxaline derivative compounds and their use in treating diseases, such as cancer, including their preparation and pharmaceutical compositions.

USPTO Abstract

The invention relates to new quinoxaline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Drugs covered by this patent

Patent Metadata

Patent number
US9902714
Jurisdiction
US
Classification
Formulation
Expires
2035-03-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Astex Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.